Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43628   clinical trials with a EudraCT protocol, of which   7211   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2012-003457-28
    Sponsor's Protocol Code Number:CC-486-AML-001
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2012-12-21
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2012-003457-28
    A.3Full title of the trial
    A phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission
    Estudio fase 3, aleatorizado, doble ciego y controlado con placebo para comparar la eficacia y la seguridad de azacitidina oral más el mejor tratamiento de apoyo frente al mejor tratamiento de apoyo como terapia de mantenimiento en pacientes con leucemia mieloide aguda en remisión completa
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care
    Versus Placebo and Best Supportive Care in Subjects with Acute Myeloid Leukemia (AML) no longer experiences symptoms of the disease
    La eficacia y la seguridad de azacitidina oral más el mejor tratamiento de apoyo frente al mejor tratamiento de apoyo como terapia de mantenimiento en pacientes con leucemia mieloide aguda que ya no experimentan síntomas de la enfermedad
    A.3.2Name or abbreviated title of the trial where available
    QUAZAR AML maintenance
    A.4.1Sponsor's protocol code numberCC-486-AML-001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCelgene Corporation
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCelgene Corporatiron
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCelgene Corporation
    B.5.2Functional name of contact pointClinicalTrialDisclosure
    B.5.3 Address:
    B.5.3.1Street Address9900 W. 109th Street, Suite 300, Building 70, Overland Park
    B.5.3.2Town/ cityKansas
    B.5.3.3Post code66210
    B.5.3.4CountryUnited States
    B.5.4Telephone number+18882601599
    B.5.5Fax number+19134513459
    B.5.6E-mailClinicalTrialDisclosure@celgene.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/07/509
    D.3 Description of the IMP
    D.3.1Product nameAzacitidina Oral
    D.3.2Product code CC-486
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAZACITIDINA
    D.3.9.1CAS number 320-67-2
    D.3.9.4EV Substance CodeSUB05624MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/07/509
    D.3 Description of the IMP
    D.3.1Product nameAzacitidina Oral
    D.3.2Product code CC-486
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAZACITIDINA
    D.3.9.1CAS number 320-67-2
    D.3.9.4EV Substance CodeSUB05624MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Acute Myeloid leukemia in complete remission
    Terapia de mantenimiento de la leucemia mieloide aguda (LMA) en pacientes de 55 años o más de edad, que se encuentran en la primera remisión completa.
    E.1.1.1Medical condition in easily understood language
    Acute Myeloid Leukemia (AML) no longer experiences symptoms of the disease
    Pacientes con leucemia mieloide aguda que ya no experimentan síntomas de la enfermedad
    E.1.1.2Therapeutic area Diseases [C] - Blood and lymphatic diseases [C15]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level PT
    E.1.2Classification code 10000881
    E.1.2Term Acute myeloid leukaemia (in remission)
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the study is to demonstrate if maintenance therapy with oral azacitidine improves OS compared with placebo in subjects with AML, age >= 55 years, who have achieved first CR or CRi after induction with intensive chemotherapy with or without consolidation chemotherapy
    El objetivo principal del estudio consiste en demostrar si la terapia de mantenimiento con azacitidina oral mejora la supervivencia global (SG) en comparación con placebo en pacientes con LMA, de edad >= 55 años y que han logrado la primera remisión completa (RC) o remisión completa con recuperación incompleta del hemograma (RCi) después de la inducción con quimioterapia intensiva, con o sin quimioterapia de consolidación.
    E.2.2Secondary objectives of the trial
    - To determine relapse-free survival ;
    - To determine safety, tolerability; and
    - To determine the effect of oral azacitidine compared with placebo on HRQoL and healthcare resource utilization.

    Exploratory objectives:

    - To determine complete cytogenetic remission rate;
    - To evaluate molecular and/or cellular markers in the bone marrow post-induction and during maintenance therapy that may be predictive of clinical outcomes with therapy (placebo or oral azacitidine), including OS and RFS, following CR/CRi; and
    - To evaluate exploratory HRQoL measures.
    Los objetivos secundarios del estudio son:
    ?Determinar la supervivencia sin recidivas (SSR).
    ?Determinar la seguridad, la tolerabilidad; y
    ?Determinar el efecto de azacitidina oral en comparación con placebo sobre la calidad de vida relacionada con la salud (CVRS) y la utilización de recursos sanitarios.
    Objetivos exploratorios

    Los objetivos exploratorios del estudio son:
    ?Determinar la tasa de remisión citogenética completa (RCc).
    ?Evaluar marcadores moleculares y celulares en la médula ósea tras la inducción y durante la terapia de mantenimiento que puedan ser predictivos de resultados clínicos con el tratamiento (placebo o azacitidina oral), como SG y SSR, después de una RC/RCi; y
    ?Evaluar variables de CVRS exploratorias.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Male or female subjects >= 55 years of age at the time of signing the ICD;
    2. Newly diagnosed, histologically confirmed de novo AML or AML secondary to prior myelodysplastic disease;
    3. Should have undergone induction therapy with intensive chemotherapy with or without consolidation therapy;
    4. Should have achieved first CR/CRi status within 3 months prior to randomization, as evidenced in the table (see protocol);
    5. ECOG performance status of 0, 1, 2 or 3;
    6. Adequate bone marrow function based on ANCs >= 0.5 x 109/L and platelet counts >= 20,000 x 109/L
    7. Adequate organ function, defined as:
    ? Serum bilirubin <=1.5 times the upper limit of normal;
    ? Serum aspartate aminotransferase and alanine aminotransferase <=2.5 times the ULN;
    ? Serum creatinine <= 2.5 times the ULN;
    8. FCBP may participate, providing they meet the following conditions:
    ? Agree to practice abstinence; or
    ? Agree to use at least two effective contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study, and for 3 months following the last dose of oral azacitidine; and
    ? Have a negative serum pregnancy test (sensitivity of at least 25 mIU/mL) at screening; and
    ? Have a negative serum or urine pregnancy test (Investigator?s discretion) within 72 hours prior to starting study therapy in the double-blind treatment phase (note that the screening serum pregnancy test can be used as the test prior to starting study therapy in the double-blind treatment phase if it is performed within the 72 hour timeframe).
    9. Male subjects with a female partner of childbearing potential must agree to practice abstinence or to the use of a physician-approved contraceptive method throughout the course of the study and avoid fathering a child during the course of the study and for 3 months following the last dose of azacitidine.
    1.Varón o mujer con una edad >= 55 años en el momento de firmar el DCI.
    2.LMA de novo o LMA secundaria a un síndrome mielodisplásico previo de reciente diagnóstico y confirmada histológicamente.
    3.Sometido a un tratamiento de inducción con quimioterapia intensiva, con o sin tratamiento de consolidación.
    4.Consecución de la primera RC/RCi en los 3 meses previos a la aleatorización, a juzgar por la tabla (ver protocolo).
    5.Estado funcional del ECOG de 0, 1, 2 o 3
    6.Función adecuada de la médula ósea a tenor de un RAN >= 0,5 x 109/l y un recuento de plaquetas >= 20.000 x 109/l.
    7.Función orgánica adecuada, definida como:
    ?Bilirrubina sérica <= 1,5 veces el límite superior de la normalidad (LSN).
    ?Aspartato aminotransferasa (AST) y alanina aminotransferasa (ALT) séricas <= 2,5 veces el LSN.
    ?Creatinina sérica <= 2,5 veces el LSN.
    8.Las MEF podrán participar, siempre que cumplan las siguientes condiciones:
    ?Se comprometen a practicar abstinencia o
    ?Se comprometen a utilizar al menos dos métodos anticonceptivos eficaces (anticonceptivos hormonales orales, inyectables o implantables, ligadura de trompas, dispositivo intrauterino, anticonceptivo de barrera con espermicida o vasectomía de la pareja) durante todo el estudio y durante los 3 meses siguientes a la última dosis de azacitidina oral, y
    ?Prueba de embarazo en suero negativa (sensibilidad de al menos 25 mUI/ml) en el momento de selección, y
    ?Prueba de embarazo en suero u orina negativa (a criterio del investigador) en las 72 horas previas al inicio del tratamiento del estudio en la fase de tratamiento doble ciego (la prueba de embarazo en suero de selección podrá utilizarse como prueba antes del inicio del tratamiento del estudio en la fase de tratamiento doble ciego en caso de realizarse en el plazo de 72 horas).
    9.Los Varones con una pareja en edad fértil deberán comprometerse a practicar abstinencia o a utilizar un método anticonceptivo aprobado por el médico durante todo el estudio y tendrán que evitar engendrar un hijo durante el estudio y durante 3 meses después de la última dosis de azacitidina.
    10.Comprensión y firma voluntaria de un DCI antes de realizar las evaluaciones y procedimientos relacionados con el estudio.
    11.Capacidad de cumplir el calendario de visitas del estudio y los demás requisitos del protocolo.
    12.Capacidad de tragar la medicación del estudio.
    E.4Principal exclusion criteria
    1. Suspected or proven acute promyelocytic leukemia (FAB M3) based on morphology, immunophenotype, molecular assay, or karyotype; or AML with previous hematologic disorder such as chronic myeloid leukemia or myeloproliferative neoplasms, excluding MDS;
    2. AML associated with inv(16), t(8;21), t(16;16), t(15;17), or t(9;22) karyotypes or molecular evidence of such translocations;
    3. Prior bone marrow or stem cell transplantation;
    4. Have achieved CR/CRi following therapy with hypomethylating agents;
    5. Received therapy with hypomethylating agents for MDS and went on to develop AML within four months of discontinuing the therapy with hypomethylating agents;
    6. Proven central nervous system leukemia;
    7. Candidate for allogeneic bone marrow or stem cell transplant at screening;
    8. Diagnosis of malignant disease within the previous 12 months (excluding basal cell carcinoma of the skin without complications, ?in-situ? carcinoma of the cervix or breast, or other local malignancy excised or irradiated with a high probability of cure);
    9. Unstable angina, significant cardiac arrhythmia, or New York Heart Association class 3 or 4 congestive heart failure
    10. Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment);
    11. Known active viral infection with known human immunodeficiency virus or viral hepatitis type B or C ;
    12. Known or suspected hypersensitivity to azacitidine or mannitol;
    13. Use of any other experimental drug or therapy within 28 days prior to Day 1 of Cycle 1.
    1. Sospecha o certeza de leucemia promielocítica aguda (FAB M3) a tenor de la morfología, inmunofenotipo, análisis molecular o cariotipo o de LMA con trastorno hematológico previo, como leucemia mieloide crónica o neoplasias mieloproliferativas, con exclusión de SMD.
    2. LMA asociada a cariotipos inv(16), t(8;21), t(16;16), t(15;17) o t(9;22) o datos moleculares de dichas translocaciones.
    3. Trasplante de médula ósea o células madre previo.
    4. Consecución de una RC/RCi después del tratamiento con fármacos hipometilantes.
    5. Ser tratado con fármacos hipometilantes por SMD y aparición de una LMA en los cuatro meses siguientes a la suspensión del tratamiento con fármacos hipometilantes.
    6. Leucemia del sistema nervioso central confirmada.
    7. Candidato para recibir un alotrasplante de médula ósea o trasplante de células madre en el momento de selección.
    8. Diagnóstico de enfermedad maligna en los 12 meses previos (salvo carcinoma basocelular de piel sin complicaciones, carcinoma ?in situ? de cuello uterino o de mama u otra neoplasia maligna local extirpada o irradiada con una elevada probabilidad de curación).
    9. Angina de pecho inestable, arritmia cardíaca significativa o insuficiencia cardíaca congestiva de clase 3 o 4 según la New York Heart Association (NYHA) (apéndice D).
    10. Infección micótica, bacteriana o viral sistémica no controlada (definida como la presencia de signos y síntomas persistentes relacionados con la infección sin mejoría a pesar del tratamiento apropiado con antibióticos o con cualquier otro tratamiento).
    11. Infección vírica activa conocida por el virus de la inmunodeficiencia humana (VIH) o el virus de la hepatitis B (VHB) o C (VHC).
    12. Hipersensibilidad conocida o sospechada a azacitidina o manitol.
    13. Uso de cualquier otro fármaco o tratamiento experimental en los 28 días previos al día 1 del ciclo 1.
    14. Falta de disposición o incapacidad de cumplimentar las evaluaciones de resultados comunicados por los pacientes sin ayuda o con una ayuda mínima del personal del centro o un cuidador con formación.
    15. Toda situación, incluida la presencia de anomalías analíticas, que entrañe un riesgo inaceptable para el paciente en caso de participar en el estudio.
    16. Cualquier enfermedad, anomalía analítica o trastorno psiquiátrico importante que interfiera o impida participar en el estudio al paciente.
    17. Cualquier situación que altere la capacidad de interpretar los datos del estudio.
    18. Cualquier trastorno que provoque una incapacidad de tragar comprimidos.
    19. Cualquier trastorno que pueda dificultar la absorción de la medicación del estudio (por ejemplo, intestino corto o síndrome de malabsorción)
    E.5 End points
    E.5.1Primary end point(s)
    Overall Survival
    Supervivencia global
    E.5.1.1Timepoint(s) of evaluation of this end point
    Estimated at 60 months after study initiation (approx. 330 deaths in total)
    Plazo aproximado de 60 meses desde el inicio del estudio (aprox 330 muertes en total)
    E.5.2Secondary end point(s)
    - RFS;
    -Time to relapse from CR/CRi;
    -Time to discontinuation from treatment;
    -Safety / tolerability (type, frequency, severity, and relationship of AEs to study treatments; physical examinations, vital signs; clinical laboratory evaluations, and concomitant medication/therapy);
    - Patient-reported outcomes utilizing the FACIT-Fatigue Scale and the EQ-5D; and
    - Measures of healthcare resource utilization
    Los criterios de valoración secundarios del estudio serán:
    ?SSR.
    ?Tiempo transcurrido hasta la recidiva a partir de la RC/RCi.
    ?Tiempo transcurrido hasta la suspensión del tratamiento.
    ?Seguridad/tolerabilidad (tipo, frecuencia, intensidad y relación de los AA con los tratamientos del estudio, exploraciones físicas, constantes vitales, pruebas analíticas y medicación/tratamiento concomitante).
    ?Resultados comunicados por los pacientes según los cuestionarios FACIT escala de cansancio y EQ 5D y
    ?Variables de utilización de recursos sanitarios.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Estimated at 60 months after study initiation (approx. 330 deaths in total)
    Plazo aproximado de 60 meses desde el inicio del estudio (aprox 330 muertes en total)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned12
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA76
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Belgium
    Czech Republic
    Denmark
    Finland
    Germany
    Israel
    Italy
    Korea, Republic of
    Lithuania
    Mexico
    Norway
    Poland
    Portugal
    Spain
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The study will conclude once the total number of events (n=330 deaths) have occurred.
    El estudio concluye una vez que el número total de eventos (n = 330 muertes) se hayan producido
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 115
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 345
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state43
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 300
    F.4.2.2In the whole clinical trial 460
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Standard of care
    Estándar de tratamiento
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-01-16
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-01-10
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA